ArticleInternational journal of women's health2026
CXCL8 Promotes the Progression of Vulvar Squamous Cell Carcinoma and Serves as a Potential Prognostic Biomarker.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vulvar squamous cell carcinoma (VSCC), although rare, poses substantial clinical challenges due to frequent late-stage diagnosis, quality-of-life-impairing surgical interventions, and the availability of limited therapeutic options following recurrence. Therefore, exploration of the pathogenesis of vulvar cancer, and identification of effective therapeutic targets based on the biological pathways of disease progression, offer great value in improving patients' survival duration and quality of life. Patients and Methods: Herein, we investigated the influence of C-X-C motif chemokine ligand 8 (CXCL8) on the proliferation of vulvar squamous cancer cells and the underlying mechanisms, as well as their influence on the prognosis of patients with VSCC. Results: Using a combination of RNA sequencing and Gene Expression Omnibus (GEO) database analysis, CXCL8 was identified as a differentially expressed gene in vulvar cancer tissue in comparison with adjacent normal tissue. Immunohistochemical analysis of selected clinical specimens revealed that CXCL8 was statistically upregulated in vulvar squamous cancer tissues in comparison with adjacent normal tissue, and this upregulation was correlated with shorter progression-free survival and overall survival. Functional assays demonstrated that CXCL8- mediated proliferation enhancement in VSCC cell lines (SW962/A431) in a dose- and time-dependent manner. Cell cycle analysis showed that exogenous CXCL8 drove a G0/G1-to-G2/M phase transition in SW962 and A431 cells. Transcriptomic profiling explored CXCL8-activated pathways, including cytokine-cytokine receptor interaction, transforming growth factor (TGF)-β signaling pathway, and tryptophan metabolism. Conclusion: These findings highlight CXCL8 as a potential prognostic biomarker for VSCC and underscore its role in driving tumor proliferation, providing a rationale for targeting CXCL8 in vulvar cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.